C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.410
-0.210 (-8.02%)
At close: Mar 27, 2026, 4:00 PM EDT
2.430
+0.020 (0.83%)
After-hours: Mar 27, 2026, 7:58 PM EDT

C4 Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
235185254---
Market Cap Growth
63.99%-27.20%----
Enterprise Value
-1.95-9.8269.33000
Last Close Price
2.411.913.605.655.9032.20
PE Ratio
--1.50-2.37-2.12-2.25-17.69
PS Ratio
6.545.157.15---
PB Ratio
0.910.721.18---
P/TBV Ratio
0.780.621.16-1.003.81
P/FCF Ratio
--1.86-3.89---
P/OCF Ratio
--1.88-3.90---
EV/Sales Ratio
--0.271.95---
EV/EBITDA Ratio
-0.09-0.59---
EV/EBIT Ratio
-0.09-0.58---
EV/FCF Ratio
-0.10-1.06---
Debt / Equity Ratio
0.210.210.28-0.280.11
Debt / EBITDA Ratio
-0.53-0.53-0.56--0.68-0.53
Debt / FCF Ratio
-0.60-0.60-1.01--0.78-0.49
Net Debt / Equity Ratio
-0.73-0.73-0.83--0.65-0.68
Net Debt / EBITDA Ratio
1.671.671.52-1.483.30
Net Debt / FCF Ratio
1.901.902.74-1.703.02
Asset Turnover
0.100.100.2000.070.10
Quick Ratio
7.607.605.49-6.236.15
Current Ratio
7.817.815.71-6.466.36
Return on Equity (ROE)
-44.38%-44.38%-97.40%0.00%-37.76%-25.03%
Return on Assets (ROA)
-32.52%-32.52%-68.43%0.00%-27.63%-18.11%
Return on Invested Capital (ROIC)
-127.76%-127.76%-284.77%0.00%-82.74%-85.28%
Return on Capital Employed (ROCE)
-36.55%-36.55%-78.58%0.00%-30.78%-20.23%
Earnings Yield
-44.65%-66.49%-42.22%-47.26%-44.41%-5.65%
FCF Yield
-42.23%-53.65%-25.70%---
Buyback Yield / Dilution
-19.49%-19.49%-39.75%-1.59%-6.12%-304.93%
Total Shareholder Return
-19.49%-19.49%-39.75%-1.59%-6.12%-304.93%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q